According to Zacks, “Cullinan Management Inc. is a biopharmaceutical company. It is focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies for cancer patients. Cullinan Management Inc. is based in CAMBRIDGE, Mass. “
Other equities research analysts have also recently issued research reports about the stock. HC Wainwright raised their price objective on shares of Cullinan Oncology from $48.00 to $55.00 and gave the stock a buy rating in a research note on Friday, June 4th. SVB Leerink increased their target price on Cullinan Oncology from $48.00 to $54.00 and gave the company an outperform rating in a research report on Friday, June 4th. Finally, Morgan Stanley increased their target price on Cullinan Oncology from $40.00 to $43.00 and gave the company an overweight rating in a research report on Monday, June 7th. Five equities research analysts have rated the stock with a buy rating, Cullinan Oncology presently has a consensus rating of Buy and an average price target of $47.40.
Several large investors have recently modified their holdings of CGEM. The Manufacturers Life Insurance Company acquired a new stake in shares of Cullinan Oncology during the 1st quarter worth about $308,000. Victory Capital Management Inc. acquired a new stake in shares of Cullinan Oncology during the 1st quarter worth about $1,445,000. Rhumbline Advisers acquired a new position in Cullinan Oncology in the 1st quarter valued at about $483,000. The PNC Financial Services Group Inc. acquired a new position in Cullinan Oncology in the 1st quarter valued at about $306,000. Finally, American International Group Inc. acquired a new position in Cullinan Oncology in the 1st quarter valued at about $319,000. 71.97% of the stock is owned by hedge funds and other institutional investors.
Cullinan Oncology Company Profile
Cullinan Management, Inc, a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with non-small cell lung cancer.
Recommended Story: Short Selling
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Cullinan Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Oncology and related companies with MarketBeat.com's FREE daily email newsletter.